treatment of Cushing's syndrome Uses in dogs Indications Treatment history Mechanism The treatment of advanced breast cancer
ChemicalBook > CAS DataBase List > Trilostane

Trilostane

treatment of Cushing's syndrome Uses in dogs Indications Treatment history Mechanism The treatment of advanced breast cancer
Trilostane Structure
Trilostane
  • CAS No.13647-35-3
  • Chemical Name:Trilostane
  • CBNumber:CB4768762
  • Molecular Formula:C20H27NO3
  • Formula Weight:329.43
  • MOL File:13647-35-3.mol
Trilostane Property
  • Melting point 264 °C
  • alpha D25 +137.4° (c = 1 in pyridine)
  • Boiling point 467.02°C (rough estimate)
  • Density 1.1213 (rough estimate)
  • refractive index 1.5614 (estimate)
  • storage temp. 2-8°C
  • solubility DMSO: ≥17mg/mL
  • form powder
  • pka 8.57±0.70(Predicted)
  • color white to tan
  • InChIKey KVJXBPDAXMEYOA-CXANFOAXSA-N
  • SMILES [C@@]123CC[C@@]4([H])[C@]5([H])CC[C@H](O)[C@@]5(C)CC[C@]4([H])[C@@]1(C)CC(C#N)=C(O)[C@@]2([H])O3 |&1:0,3,5,9,11,15,17,25,r|
  • CAS DataBase Reference 13647-35-3(CAS DataBase Reference)
  • FDA UNII L0FPV48Q5R
  • NCI Drug Dictionary Modrastane
  • ATC code H02CA01
  • Proposition 65 List Trilostane
  • EPA Substance Registry System Trilostane (13647-35-3)
  • UNSPSC Code 51111800
  • NACRES NA.77
Safety
Hazard and Precautionary Statements (GHS)
  • Symbol(GHS)
  • Signal wordWarning
  • Hazard statements H315-H319-H361
  • Precautionary statements P201-P302+P352-P305+P351+P338-P308+P313
Trilostane Price More Price(2)
  • Brand: Sigma-Aldrich(India)
  • Product number: SML0141
  • Product name : Trilostane
  • Purity: ≥98% (HPLC)
  • Packaging: 10MG
  • Price: ₹12849.28
  • Updated: 2022/06/14
  • Buy: Buy
  • Brand: Sigma-Aldrich(India)
  • Product number: SML0141
  • Product name : Trilostane
  • Purity: ≥98% (HPLC)
  • Packaging: 50MG
  • Price: ₹53475.5
  • Updated: 2022/06/14
  • Buy: Buy

Trilostane Chemical Properties,Usage,Production

  • treatment of Cushing's syndrome Trilostane is an inhibitor of 3β-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome and primary hyperaldosteronism. These are both disorders where excess amounts of corticosteroid hormones are produced in the body. Corticosteroids are essential for the body to make use of carbohydrates, fats and proteins and for a normal response to stress. They are also necessary for the regulation of salt and water balance in the body. Trilostane helps prevent the production of corticosteroids, controlling the symptoms associated with these disorders.
    Trilostane can also be useful in the treatment of breast cancer that has relapsed in women who have gone through menopause.
  • Uses in dogs Trilostane was withdrawn from the United States market in April 1994. However, it was approved in 2008 for the treatment of Cushing's disease (hyperandrenocorticism) in dogs.
    It is also the first drug approved to treat both pituitary-and adrenal-dependent Cushing's in dogs.
    1. has kidney or liver disease.
    2. takes certain medications used to treat heart disease.
    3. pregnant.
    4. taking other medicines, including those available to buy without a prescription, herbal or complementary medicines.
    5. had an allergic reaction to this or any other medicine.
  • Indications Trilostane can inhibit 3β-dehydrogenase in the synthesis of corticosteroids, and decrease the synthesis of cortisol and aldosterone. It also can be used in the treatment of Cushing's syndrome (hypercortisolism) and primary aldosteronism. But the efficacy to treat Cushing's syndrome (hypercortisolism) is not as metyrapone. This product also has a significant role in lowering blood testosterone levels, which may be related with that its synthesis is inhibited.
  • Treatment history Trilostane, that is 4α, 5α-epoxy-2-cyano-3,17β-diol, can reversibly inhibit 3β-hydroxy steroid dehydrogenase and △5, 4-isomerase in the adrenal cortex to block the biosynthesis of mineralocorticoid and glucocorticoid. In 1980, it was approved for the treatment of hyperaldosteronism and cortisol excess disease in the United Kingdom. In 1985, it was approved for the treatment of Cushing's syndrome in the United States, which is adrenal cortex hyperactivity disorder. In view of the older animals, especially older dogs are susceptible to Cushing's syndrome. Trilostane can relieve the disease symptoms of more than 90% of dogs, and improve their quality of life. So the drug has also been granted for the treatment of animals in the United Kingdom. Trilostane itself has no hormonal activity. Its side effects is less, and its safety and tolerability are also particularly good.
    The above information is edited by the chemicalbook of Ge Qian.
  • Mechanism Breast cancer is one of hormone-dependent tumors. And estrogen is the main driving factor of the growth of breast cancer cells. Thus, one of the modern treatment of breast cancer is the major target of estrogen through inhibiting the production of estrogen or block the action of estrogen or estrogen receptor in its site of action. It has been known that estrogen receptor is only a single receptor, but recent studies have identified that there are at least two subtypes α and β. Estrogen uniting with α-estrogen can stimulate cell growth, but it uniting with β-estrogen receptor can cut α-estrogen receptors and slow the rate of cell proliferation. Research revealed that the trilostane cannot only lower the production of estrogen, but also can modulate the binding of estrogen receptors on different subtypes. And meanwhile the dual effect of α-estrogen receptor inhibitors and β-estrogen receptor appears. Finally it can block and alter the negative effect of estrogen on cancer cells. The unique mode of action of trilostane can not only set it apart from other existing anti-estrogen drugs, but also be the pharmacological basis of that it is still highly effective on breast cancer in treatment failure with other anti-estrogen therapy or resistant breast cancer.
  • The treatment of advanced breast cancer Breast cancer is the most common type of tumor in women. Currently, for postmenopausal patients with hormone receptor-positive or unknown, clinical treatments unanimously recommend to be the preferred antiestrogen therapy, and the role of this therapy in delaying disease progression and improving survival time also has been affirmed and confirmed in numerous studies of breast cancer.
    Trilostane (trade name Modrenal) developed by the biotechnology company has already been on the market. It can be used for the treatment of postmenopausal women that hormone-selective cancer has spread outside the breast. The pharmaceutical uses two ways to slow down the disease progression. For hormone-sensitive breast cancer, estrogen promotes the growth of cancer cells by acting to the two receptors. Estrogen receptor α is cancer accelerator, and estrogen receptor β is the brake. Modrenal strengthens estrogen adsorption to the estrogen receptor β, and weakens the adsorption to estrogen receptor α. Meanwhile it also acts on another loci AP1in cell DNA to reduce cell proliferation.
  • Description 3β-hydroxysteroid dehydrogenase (3β-HSD) type 1 and type 2 isoforms are key enzymes for the biosynthesis of all active steroid hormones. 3β-HSD1 (type I) is expressed in placenta and peripheral tissues including breast tumors, whereas 3β-HSD2 (type 2) is expressed in the adrenal gland, ovary, and testis. Trilostane is an inhibitor of the 3β-HSDs: 3β-HSD1 and 3β-HSD2 with Ki values of 0.10 and 1.60 μM, respectively. Trilsotane has been approved for use in the treatment of Cushing’s syndrome in dogs to reduce cortisol, aldosterone, and corticosterone levels. Because human 3β-HSD (type 1) is a critical enzyme in the conversion of DHEA to estradiol in breast tumors, trilostane is also of interest for the treatment of breast cancer in postmenopausal women.
  • Chemical Properties Tan Crystals
  • Originator Modrenal,Sterling Winthrop,UK,1980
  • Uses An inhibitor of steroid biosynthesis. Used as an adrenocortical suppressant. Used in the treatment of breast cancer.
  • Uses antifungal, inhibits mitosis in metaphase
  • Uses Trilostane has been used to evaluate its capability to regulate the sex-dependent differences in the lipopolysaccharide (LPS)-induced inflammatory responses of astrocytes.
  • Definition ChEBI: Trilostane is an epoxy steroid that is 3,17beta-dihydroxy-5alpha-androst-2-ene-2-carbonitrile in which the oxygen of the epoxy group is joined to the 4alpha and 5 alpha positions. It has a role as an antineoplastic agent, an abortifacient and an EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor. It is a 3-hydroxy steroid, a 17beta-hydroxy steroid, an androstanoid, an epoxy steroid and a nitrile.
  • Manufacturing Process (A)17β-acetoxy-4α,5α-epoxyandrostano[2,3-d]isoxazole, melting point 228.6°C to 229.8°C (corrected) recrystallized from a benzene-methanol mixture, [α]D25 = +76.5°C (1% in chloroform), was prepared by treating 17β- acetoxy-4-androsteno[2,3-d] isoxazole with maleic anhydride and hydrogen peroxide in methylene dichloride solution.
    (B)2α-cyano-4α,5α-epoxandrostan-17β-ol-3-one was prepared by treating 17β-acetoxy-4α,5α-epoxyandrostano[2,3-d] isoxazole with sodium methoxide, and was obtained in the form of tan crystals, melting point 257.8°C to 270.0°C (decomposition) (corrected) when recrystallized from a pyridine_x0002_dioxane mixture.
  • brand name Modrastane (Bioenvision).
  • Therapeutic Function Corticosteroid antagonist
  • General Description Trilostane inhibits the production of adrenal steroids, such as cortisol and aldosterone. It is used to treat aldosteronism.
  • Biochem/physiol Actions Trilostane is an inhibitor of 3 β-hydroxysteroid dehydrogenase (3-β-HSD or delta 5-delta 4-isomerase), an essential enzyme for the biosynthesis of all classes of hormonal steroids. It has been used in the treatment of Cushing′s syndrome for stopping the production of cortisol, and is currently approved for dogs in the US, but is still a human drug in the UK and other countries. It is being investigated as a possible treatment for both breast cancer and prostate cancer to prevent the synthesis of estrogens and androgens from endogenous precursors. It has also been used to inhibit endogenous production of progesterone in research studies.
  • Veterinary Drugs and Treatments Trilostane may be useful for treating pituitary-dependent hyperadrenocorticism or adrenal dependent hyperadrenocorticism in dogs, feline pituitary-dependent hyperadrenocorticism, and equine hyperadrenocorticism (HAC). It may also be useful in treating Pomeranians with Alopecia X and Alaskan malamutes with adultonset alopecia.
Trilostane Preparation Products And Raw materials
Raw materials
Preparation Products
Trilostane Suppliers
Global(376)Suppliers

Related articles

Trilostane Spectrum
13647-35-3, TrilostaneRelated Search:
  • APIs
  • FULVICIN
  • Inhibitor
  • Steroids
  • Pharmaceuticals
  • Intermediates & Fine Chemicals
  • 杂质
  • 有机中间体
  • 精细化学系列
  • 杂质对照品
  • 抑制剂
  • 试剂
  • 兽用原料系列
  • FDA批准的配体
  • 优势 主打 产品
  • 兽药
  • 医药化工产品
  • 兽用
  • 原料药
  • 有机化工原料
  • 皮质激素
  • 日用化学品
  • 化学试剂
  • 医用原料
  • 优势产品
  • 原料
  • 医药 抗雌激素新药
  • 原料药及其中间体
  • 科研试剂
  • 抗肿瘤类药物及免疫抑制剂
  • 中间体
  • 医药原料
  • 抗肿瘤原料药，也可用于动物身上
  • 小分子抑制剂
  • 有机原料
  • 医药原料药
  • 3647-35-3
  • 曲洛司坦,10 MM DMSO 溶液
  • 曲洛司坦-D3同位素
  • (1AS,4AR,4BS,6AS,7S,9AS,9BS,11AR)-2,7-二羟基-4A,6A-二甲基-1A,4,4A,4B,5,6,6A,7,8,9,9A,9B,10,11-十四氢环戊烷并[7,8]菲并[1,10A-B]环氧基-3-碳腈
  • 曲洛司坦(对照品)
  • 化合物LY2109761
  • 曲洛司坦 ( 曲洛斯坦)
  • 三氯司坦
  • 犬类专属疾病用药-曲洛司坦
  • 曲洛司坦/ 亚硝酸盐环氧雄烷
  • 曲洛司坦(标准品)
  • 曲洛斯坦(亚硝酸盐环氧雄烷)
  • 曲洛斯坦
  • 亚硝酸盐环氧雄烷
  • 曲龙斯坦(亚硝酸盐环氧雄烷)
  • 曲洛司坦
  • 曲龙斯坦
  • 13647-35-3
  • Trilostane - Bio-X ?
  • Trilostane, 10 mM in DMSO
  • Trostan*
  • (1aS,4aR,4bS,6aS,7S,9aS,9bS,11aR)-2,7-Dihydroxy-4a,6a-dimethyl-1a,4,4a,4b,5,6,6a,7,8,9,9a,9b,10,11-tetradecahydrocyclopenta[7,8]phenanthro[1,10a-b]oxirene-3-carbonitrile

Home

My